Drug Trial Radar · NCT04697810
Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Last checked: Nov 19, 2026Latest source record: Jul 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
114
Planned (sponsor's estimate)
Start
Dec 10, 2021
Primary completion
Apr 15, 2025
Study completion Oct 15, 2025
Sponsor
- Lead sponsor
- Can-Fite BioPharmaIndustry
- Sponsor type
- Industry
- First posted
- Jan 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Subjects with biopsy-proven NASH will be randomly assigned in a 2:1 ratio to oral doses of namodenoson 25 mg every 12 hours or matching placebo every 12 hours for 36 weeks. Subjects will be evaluated regularly for safety, and efficacy biomarkers will be measured at Baseline and Weeks 6, 12, 24, and 36. At Week 36, all subjects will undergo liver biopsy.
Conditions
- NASH - Nonalcoholic Steatohepatitis
Interventions
NamodenosonDrug
25 mg q12hours x 36 weeks
PlaceboDrug
Matching capsules q12hours x 36 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Non-Alcoholic Fatty Liver Disease (NAFLD) activity score (NAS)Time frame: 36 weeks
- Adverse events (AEs)Time frame: 36 weeks
Locations
24 sites in 6 countries. Site status is shown where the registry gives one.
941 Univ of Clinical Centre of the Republic of Srpska
Banja Luka, Bosnia and Herzegovina · Not yet recruiting
942 Health Inst General Hospital, Dept of Internal Medicine
Prijedor, Bosnia and Herzegovina · Not yet recruiting
934 Second Dept of Internal Disease, MHAT Sveta Karidad EAD
Plovdiv, Bulgaria · Not yet recruiting
932 Office of Gastroenterology, Medical Center Sansi EOOD
Rousse, Bulgaria · Not yet recruiting
931 Clinic of Gastroenterology, Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda EAD, Sofia
Sofia, Bulgaria · Not yet recruiting
933 Clinic of Gastroenterology, University Multiprofile Hosptial for Active Treatment
Sofia, Bulgaria · Not yet recruiting
935 Dept of Gastroent., Univ Multiprofile Hospital for Active Treatment and Emergency Medicine
Sofia, Bulgaria · Not yet recruiting
936 Office of Gastroenterology, Diagnostic - Consultative Center XX
Sofia, Bulgaria · Not yet recruiting
937 Office of Gastroenterology, Diagnostic - Consultative Center Alexandrovska
Sofia, Bulgaria · Not yet recruiting
938 Clinic of Gastroenterology, University Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski"
Sofia, Bulgaria · Not yet recruiting
517 Saroka University Medical Center
Beersheba, Israel · Recruiting
Hadassah Medical Center
Jerusalem, Israel · Active not recruiting
911 IMSP Spitalul Clinic Republican "Timofei Mosneaga"
Chisinau, Moldova · Recruiting
912 SP Spitalul Ministerului Sanatatii, Muncii si Protectiei Sociale
Chisinau, Moldova · Not yet recruiting
903 Central Pentru Studiul Metabolismului
Bucharest, Romania · Recruiting
904 SUUMC Carol Davilla, Department Diabet
Bucharest, Romania · Recruiting
906 Spitalul Sfanta Maria
Bucharest, Romania · Recruiting
902 Cluj County Clinical Emergency Hospital, 3rd Dept of Internal Medicine
Cluj-Napoca, Romania · Recruiting
901 Medical Center Dr. Ianosi
Craiova, Romania · Recruiting
905 County Hospital Timisoara
Timișoara, Romania · Recruiting
922 UCC Zvezdara Belgrade
Belgrade, Serbia · Not yet recruiting
923 Military Medical Academy Belgrade
Belgrade, Serbia · Not yet recruiting
924 CHC "dr Dragisa Misovic" - Dedinje Belgrade
Belgrade, Serbia · Not yet recruiting
921 UCC Nis
Niš, Serbia · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.